Smartphone cameras and pregnancy test-like procedure can speed up Urinary Tract Infection diagnosis
A new test developed by a team of biological engineers led by CSCT academic Dr Nuno Reis could simplify initial diagnosis of urinary tract infections (UTIs) by using a normal smartphone camera. This development could have a significant contribution in the fight against the global threat of antibiotic resistance.
Similar in principle to a pregnancy test, the process can identify the presence of harmful E. coli bacteria in a urine sample in just 25 minutes. As well as being far faster than existing testing, it could make accurate UTI testing more widely available in developing nations and remote regions thanks to its potential to be made portable, and far more cheaply than existing lab-based tests.
E. coli is present in 80 percent of bacterial UTIs, so, if detected, it tells medical professionals that antibiotic treatment is needed. As well as a smartphone camera, the test — which could also be adapted to detect a variety of bacterial infections — takes advantage of widely-available reagents and new micro-engineered materials. Researchers say the simplicity of the test, which has now passed the proof-of-concept stage, could deliver a new way to quickly identify treatments for patients in poorer or remote regions.
Described in the journal Biosensors and Bioelectronics, the test uses antibodies to capture bacterial cells in very thin capillaries within a plastic strip, detecting and identifying the cells optically rather than through the microbiological methods currently used.
Dr Nuno Reis, who led the development of the test, says: “The test is small and portable, so it has major potential for use in primary care settings and in developing countries.
“Currently, bacterial infections in UTIs are confirmed via microbiological testing of a urine sample. This method is accurate but time-consuming, taking several days. We hope that giving medical professionals the ability to quickly rule in or rule out certain conditions will allow them to treat patients more quickly and help them make better decisions about the prescription of antibiotics.”
The lack of rapid diagnostics for UTIs has in many cases led to a catch-all prescription of potentially unnecessary antibiotics. This increases the risk of bacteria becoming resistant to treatment, which is one of the biggest threats to global health and development.
How the test works
The test is carried out by passing a urine sample over a ridged plastic micro-capillary strip, containing an immobilising antibody able to recognise E. coli bacterial cells. If E. coli is present in the sample, antibodies in the reagents will bind with it, stopping it from passing through the section of plastic strip. To finish the test, an enzyme that causes a change in colour in the strip is added — a change that can be picked up by a smartphone camera.
The system also measures the concentration of E. coli in the sample by analysing an image taken by the camera. The procedure is simple and could be manually operated or fully automated without any need for a mains power supply.
Aims to overcome regulators’ concerns on smartphone use
To date, bodies such as the United States Food & Drug Administration (FDA) have not granted approval to techniques that use smartphones, citing the potential for both non-lab conditions and software updates to the phone to make tests unscientific. However, Dr Reis hopes that this method, which uses a variable scale to digitally compare the pixels within an image, will convince regulators to allow the treatment to move toward eventual production.
Dr Reis adds that wealthier nations could also benefit from adopting the methodology, as it could make testing within primary care facilities such as GP surgeries more viable, reducing the need to send samples to central labs for testing.
He says: “The UK and wealthy countries have seen a big shift towards decentralised diagnostics, to reduce the load on national or regional labs and provide doctors with important tools to make informed diagnoses.
“Driving more of this will bring better outcomes to patients in terms of speeding up the process, but will also lower the cost to healthcare providers. We are not talking about replacing centralised diagnostics services but providing the first point of contact with affordable and rapid tools, to support the prescription of antibiotics and avoid their overuse.”
The next step in the process is clinical trials, which will require collaboration with clinical and commercial partners. Beyond this, the team will shortly begin working on refining the test to allow for the detection of other bacteria and their concentrations, which will help prescribe correct dosages and avoid antibiotic overuse.
Dr Reis concludes: “The smartphone solves one of the biggest problems of diagnostics decentralisation because their capabilities are actually very sophisticated in certain conditions. They offer the same functionality as sophisticated scanners that have, until now, been available only in labs.”